We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
IBA-Radcal

Download Mobile App




BD to Build Manufacturing Plant in China

By Labmedica staff writers
Posted on 03 Aug 2006
Becton, Dickinson and Company (BD, Franklin Lakes, NJ, USA) is investing U.S.$16 million to construct a world-class manufacturing plant in China to produce rapid diagnostic products for flu and viral infections. More...


BD Rapid Diagnostics (Suzhou) Co., Ltd., will be established in the Suzhou Export Processing Zone District B, with total investment anticipated to reach U.S.$48 million within a few years. The new plant will manufacture rapid diagnostic products for bacterial, parasitic, and viral diseases such as influenza, respiratory syncytial virus, human immunodeficiency virus (HIV), tuberculosis, and malaria. These products will be sold to countries and regions around the world, in Asia, Europe, Latin America, and the United States.

"BD will start by transferring some existing technology from one of our U.S.-based facilities,” said Mike Meehan, president, Rapid Manual Testing. We also hope that as we establish our research capability, we will be able to develop diagnostics that are very well attuned to the needs of the Chinese medical community. By locating a major plant here we hope to contribute significantly to the healthcare system in China as well as in the developing world. BD's objective is to make rapid diagnostic products accessible to a wide range of markets, in line with our purpose of ‘Helping all people live healthy lives.'”

BD Rapid Diagnostics (Suzhou) Co., Ltd. is expected to begin production in the fourth fiscal quarter of 2007, with plans to eventually manufacture products to diagnose about 30 infectious diseases. BD, a global medical technology company, makes and sells medical devices, instrumented systems, and reagents. Dedicated to improving people's health throughout the world, the company is focused on improving drug therapy, enhancing the quality and speed of diagnosing infectious diseases, and advancing research and discovery of new drugs and vaccines.



Related Links:
BD

Gold Member
Real-Time Diagnostics Onscreen Viewer
GEMweb Live
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Silver Member
X-Ray QA Device
Accu-Gold+ Touch Pro
Absorbable Monofilament Mesh
Phasix Mesh
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Surgical Techniques

view channel
Image: The AI-based approach identifies lipid regions matched well with histopathology results (Photo courtesy of Hyeong Soo Nam/KAIST)

AI-Based OCT Image Analysis Identifies High-Risk Plaques in Coronary Arteries

Lipid-rich plaques inside coronary arteries are strongly associated with heart attacks and other major cardiac events. While optical coherence tomography (OCT) provides detailed images of vessel structure... Read more

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.